Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use
-
Published:2024-05-25
Issue:1
Volume:4
Page:
-
ISSN:2730-664X
-
Container-title:Communications Medicine
-
language:en
-
Short-container-title:Commun Med
Author:
Roope Laurence S. J.ORCID, Morrell LizORCID, Buchanan James, Ledda Alice, Adler Amanda I.ORCID, Jit MarkORCID, Walker A. Sarah, Pouwels Koen B.ORCID, Robotham Julie V., Wordsworth Sarah, , Anyanwu Philip E., Borek Aleksandra J., Bright Nicole, Butler Christopher C., Campbell Anne, Costelloe Céire, Hayhoe Benedict, Holmes Alison, Hopkins Susan, Majeed Azeem, McLeod Monsey, Moore Michael, Tonkin-Crine Sarah, Wright Carla, Yadav Sara, Zalevski Anna
Abstract
AbstractBacteria are becoming increasingly resistant to antibiotics, reducing our ability to treat infections and threatening to undermine modern health care. Optimising antibiotic use is a key element in tackling the problem. Traditional economic evaluation methods do not capture many of the benefits from improved antibiotic use and the potential impact on resistance. Not capturing these benefits is a major obstacle to optimising antibiotic use, as it fails to incentivise the development and use of interventions to optimise the use of antibiotics and preserve their effectiveness (stewardship interventions). Estimates of the benefits of improving antibiotic use involve considerable uncertainty as they depend on the evolution of resistance and associated health outcomes and costs. Here we discuss how economic evaluation methods might be adapted, in the face of such uncertainties. We propose a threshold-based approach that estimates the minimum resistance-related costs that would need to be averted by an intervention to make it cost-effective. If it is probable that without the intervention costs will exceed the threshold then the intervention should be deemed cost-effective.
Funder
RCUK | Economic and Social Research Council
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Roope, L. S. J. et al. The challenge of antimicrobial resistance: what economics can contribute. Science 364, eaau4679 (2019). 2. Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. May 2016. 3. Coast, J., Smith, R., Karcher, A. M., Wilton, P. & Millar, M. Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance? Health Econ. 11, 637–647 (2002). 4. McAdams, D., Wollein Waldetoft, K., Tedijanto, C., Lipsitch, M. & Brown, S. P. Resistance diagnostics as a public health tool to combat antibiotic resistance: A model-based evaluation. PLoS Biol. 17, e3000250 (2019). 5. Broder, S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir. Res. 85, 1–8 (2010).
|
|